Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barter, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The realities of dyslipidaemia in metabolic syndrome and diabetes

Philip Barter

The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, Australia, 2050, p.barter{at}hri.org.au

High-density lipoprotein (HDL) removes excess cholesterol from macrophages in the artery wall, thereby reducing the rate of development of the cholesterol from macrophages in the artery wall, thereby reducing the rate of development of the atherosclerotic plaque. Other anti-atherogenic actions of HDL include preservation of endothelial function, inhibition of the recruitment of inflammatory cells to the developing plaque, antioxidant effects, and antithrombotic effects. Not surprisingly, large epidemiological cohort studies have identified low HDL-cholesterol (HDL-C) as a risk factor for coronary heart disease independently of levels of low-density lipoprotein cholesterol (LDL-C). Low HDL-C frequently occurs together with elevated triglycerides and the appearance of small, dense LDL, as a direct result of the metabolic changes associated with insulin resistance in conditions such as type 2 diabetes and the metabolic syndrome. The worldwide increase in these conditions and the associated increase in prevalence of low HDL-C have resulted in HDL being considered as a target for therapeutic intervention. Correction of low HDL-C should be an important target for therapy, especially in patients with type 2 diabetes and the metabolic syndrome.

Key Words: metabolic syndrome • type 2 diabetes • insulin resistance • HDL • dyslipidaemia • atherosclerosis.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 1 suppl, S7-S11 (2005)
DOI: 10.1177/14746514050050010301
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?